Parcel Biosciences

formerly ParcelBio

Elevated mRNA for transformative medicines.

San Francisco, United States · Founded 2023 · $13.5M raised

Employees
1–10
Founded
2023
Business Model
B2B
Total Funding
$13.5M
Last Round
$13.0M SeedMay 2026
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

ParcelBio is a San Francisco-based biotech startup founded in 2023 by former Orbital Therapeutics scientists, developing a new class of mRNA medicines designed to deliver unprecedented potency and durability. Its proprietary APEXm™ platform engineers mRNA to drive significantly higher and more sustained protein expression across diverse cell types, enabling therapeutic applications in autoimmune disease (in vivo CAR-T for pathogenic B cell depletion), oncology, and therapeutic protein delivery. Backed by Breyer Capital, General Catalyst, Y Combinator, and other life science investors.

Summary

Parcel Biosciences is a Biotech company based in San Francisco, United States, founded in 2023. It has raised $13.5M in total across 2 rounds, most recently a $13.0M Seed round in May 2026. Investors include Y Combinator, Breyer Capital and General Catalyst.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

SeedSeed RoundMay 2026
$13.0M

Sign up to see all 2 events

Funding: Pre-Seed through Seed. Amounts, valuations, and investors where available.

Investors

Similar Companies

Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series BTotal funding$612.0MOct 2022
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Parcel Biosciences on Indexed.vc
<a href="https://indexed.vc/companies/parcel-biosciences"><img src="https://indexed.vc/api/badge/company/parcel-biosciences" alt="Parcel Biosciences on Indexed.vc" width="260" height="76" /></a>